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ABSTRACT 
This manuscript explores ethical implications of treatment for youth with diagnosed 
gender dysphoria. The ethical condiderations outlined and analyzed in this essay 
involve illuminating an understanding of whether the administration of pubertal 
suppression with GnRH agonists, and cross-sex hormones to children with gender 
dysphoria is morally justified as treatment to manage their psychological distress, or if 
safer more understood alternatives exist. This essay emphasizes that as health care 
professionals, we must ensure youth with genger dysphoria receive adequate medical 
treatment and care. This  essay concludes through extensive literature review, that the 
use of inconclusive and underresearched methods to manage gender dysphoria cannot 
be ethically justified and therefore should be re-evaluated.  
 
Keywords: Gender dysphoria, GnRH agonists, Cross-sex hormones, Ethical implications 
 
1. Introduction 
 
 In the past few decades, individuals who self-identify as transgender and many 
whom may meet the DSM-5 diagnostic criteria for Gender Dysphoria, seem to have 
revealed their desired identities online and in their physical lives. Online, this is reflected 
through thousands, of websites, blogs, and discussion groups which provide information 
about what it means to be transgender, how to access health care, and, social support 
outlets [24]. In recent years, the number of specialised gender identity clinics have 
increased rapidly, with new programs established in Australia, Western Europe, North 
America and other areas, reporting a sharp increase in referral rates [24]. With the rise 
of these developments, it is appropriate to provide insight into the ethical implications 
which present when support for these individuals approaches underdeveloped medical 
treatment. 
 
Gender dysphoria (GD) is a condition that is marked by psychological suffering 
due to incongruence between an individual’s experienced or expressed gender and 
their biologically assigned sex [4].The manifestation of GD can be observed during 
childhood and adolescent development both in the prepubertal and postpubertal stages. 
In gender dysphoric children and adolescents, puberty initiates the development of 
undesirable sexual characteristics causing acute suffering due discordance with their 
biologically assigned sex [4]. Although the prevalence of gender dysphoria, as it is 
indicated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), remains 
a relatively uncommon diagnosis, there is sufficient evidence that its prevalence has 
increased recent decades [24]. In recent years, there has been an increase in referral 
rates to specialised gender identity clinics, underscoring the rising prevalence of this 
diagnosis. Recent studies suggest that the prevalence of a self-reported transgender 
  
 
identity in children, adolescents and adults ranges from 0.5 to 1.3%, markedly higher 
than prevalence rates based on clinic-referred samples of adults only; emphasizing the 
increasing prevalence among youth populations [24]. Pubertal suppression with 
gonadotropin releasing hormone analogs (GnRHa) have been proposed for individuals 
with GD in the pediatric and adolescent population as a treatment for postponing the 
pubertal development with the goal to attenuate psychological suffering. Pubertal 
suppression with GnRH agonists combined with cross-sex hormones in children and 
adolescents are being considered, and performed in order to decrease the adversities 
of gender dysphoria in this population.  
 
Children with gender dysphoria  experience distress over their gender 
incongruence and, if they successfully undergo the pubertal development of what they 
attribute as their incorrect gender, their psychological well-being could deteriorate 
significantly. Studied children and adolescents  in this population develop depression 
and suicidal ideation, and further may experience alienation, and harassment in their 
social environments for their inability to be socially accepted in cross-gender sports, 
restrooms or similar gender specific experiences [5]. Such circumstances may lead to 
the development of increased psychiatric morbidity. Due to these risks,  many medical 
professionals, family members of gender dysphoric children and society at large feel 
medical and psychological intervention is appropriate at addressing these concerns.  
 
Gender, is a term coined which refers to the psychological and cultural 
characteristics associated with biological sex. The term gender is a psychological and 
sociological concept. Gender dysphoria in pediatric and adolescent cases, may lead to 
the formation of a transgendered individual. Transgender refers to an individual with a 
gender identity that does not conform to expectations based on the sex they were 
assigned at birth. In simplest terms, it is a discordance between gender, identity and sex 
[1]. Identical twin studies demonstrate these psychological and sociological factors 
which predominate in the development of gender dysphoria [18]. Family and peer 
relationships, one’s ecological influences and their experiences impact an individual’s 
emotional, social, and psychological development [18].  Studies suggest that social 
reinforcement, parental psychopathology, family dynamics, and social influence 
facilitated by various forms of media, all contribute  to the development of GD in children 
[5].  
 
1.1 Treatment directions for gender dysphoric youth 
 
In the past, medicine utilized psychological interventions focusing on aligning the 
mind with the body, and addressing underlying ideologies or potential misconceptions 
treating GD as a psychological condition, not a physical one [1]. In recent years, the 
paradigm has shifted, ideology now stating that the mind is correct, and the body is 
afflicted, and new interventions focus on aligning the body to what the mind believes by 
implementing pubertal suppression with GnRH agonists, cross-sex hormones, and sex 
reassignment surgeries. For children and adolescents with gender dysphoria they may 
desire such interventions in order to establish an external appearance that more closely 
aligns with their gender identity. The debate over how to treat children and adolescents 
  
 
with GD is primarily an ethical dispute, one in which we must consider the guiding 
ethical principles on which medicine and bioethics rely. Though implementing 
appropriate interventions for  gender dysphoria in the pediatric and adolescent 
population is certainly paramount, the use of puberty suppression medications, and 
cross-gender hormone therapy in this population is not ethically acceptable. Conclusive 
and sufficient evidence of long term safety and evaluation  of potential risks such as 
adverse effects on metabolic and endocrine status, impaired increment of bone mass, 
and interference with brain development has not met evidence based medicine 
guidelines, and undermines basic ethical guiding principles.  
 
1.2 Typical puberty development in youth  
 
For a typically developing child, usually around age eleven in biological males 
and ten in biological females the pituitary gland in the brain releases two hormones- 
luteinizing hormone and follicle stimulating hormone. When these hormones are 
produced in higher concentrations they affect the sex glands in the testes (male) and 
ovaries (female) producing sex hormones testosterone and estrogen respectively [20]. 
The production of these sex hormones cause the developmental stages in puberty.   
These stages occur in a series of steps called Tanner Stages 1-5. The Tanner stages 
present in varied ages depending on the individual, the scale defines physical 
measurements of development based on external primary and secondary sex 
characteristics; breasts, genitals, testicular volume and development of pubic hair. In 
biological males, these stages enable an increase in testicular size, increasing 
testosterone production, which enable increase pubic hair and phallic size [19]. A 
typically developing male will grow axillary (armpit) hair and facial hair, and grow taller in 
height and their voice changes. In biological females, estrogen production allows for 
breast development, menstrual cycle will begin and females will experience growth of 
pubic hair, and axillary hair [20]. 
1.3 Mechanism of puberty suppression medication 
 
Puberty suppression is an agent which inhibits the the release of luteinizing 
hormone and follicle stimulating hormones from the pituitary gland [7]. Inhibiting these 
hormone prevents  testosterone from being released from the testes, and estrogen from 
being released from the ovaries. Without exposure to the sex hormones, estrogen and 
testosterone, children and adolescents of pubertal age will not undergo the physical 
changes associated with these hormones. Leuprolide or Depot Lupron is a common 
suppression drug used. They can be injected intramuscularly and given on a monthly or 
every 3-month basis. Supprelin or Histrelin is an implant version of puberty suppression 
drug. This device is implanted under the skin and releases the agent over a period of 
one year.  
 
 Puberty suppression medications are used for many different reasons. In some 
children they have been approved by the Federal Drug Administration (FDA)  for 
treatment of precocious puberty [20], which is a premature onset of puberty. In this 
case, puberty is only suppressed until a developmentally appropriate age for onset 
  
 
occurs, then puberty is continued and occurs within typical limits. In adult populations, 
puberty suppression medications are used for treatment of prostatic carcinoma in males 
and  may be used to treat endometriosis, uterine fibroids, or other female hormone-
related problems [7]. These treatment measures, have been extensively researched 
and trialed for their corresponding population, as a sufficient treatment option to 
manage otherwise detrimental health conditions [21]. Finally as stated previously, 
puberty suppression medications are now increasingly used in order to suppress 
endogenous sex hormone production in pediatric and adolescent populations with 
gender dysphoria despite minimal longitudinal, clinical and evidence based research [1].   
 
2. The case in favor of puberty suppression and similar medical interventions 
 In recent years, there has been an increase in referrals of gender-expansive and 
transgender children to specialty pediatric centers which offer gender clinics, specific for 
pediatric and adolescent populations with gender dysphoria or similar gender identity 
disorders. It is not known whether this is because of increased prevalence or increased 
recognition or acceptance of transgender communities, and other gender identity 
related diagnoses. There are now forty gender clinics across the United States that 
promote the use of pubertal suppression and cross-sex hormones in children and 
adolescent populations [1]. The rationale for use of puberty suppression is to allow the 
gender-dysphoric child time to explore gender identity free from the emotional distress 
triggered by the onset of secondary sex characteristics that typically present in the 
stages of puberty [8][6].  
There is an adequate case in favor of utilizing puberty suppression,  and cross 
gender hormones in order to address the psychological, social, and emotional concerns 
for children and adolescents faced with gender dysphoria. By suppressing the 
individual’s production of sex hormones, administering cross hormone therapy for 
transition to desired gender would be be more effective [6]. Puberty suppressive drugs 
usage would effectively inhibit the endogenous pubertal changes that may worsen the 
individual’s gender dysphoria, creating further emotional, social and psychological 
distress [6]. In fact, those who support the use of such medication indicate that 
withholding this treatment would be more harmful.   
There is evident controversy surrounding suppression of puberty in children with 
GD, however supporters have compiled minimum evidence in favor of this treatment 
option. Medical, surgical and psychological interventions are considered to be 
necessary components in the management of gender dysphoria in the adult population. 
The goals of medical and surgical treatments are to align the patient’s physical 
appearance to their internal gender identity. Medical treatment involves the 
administration of cross-sex hormones, surgical interventions such as mastectomies, 
salpingo-oophorectomies, hysterectomies, creating neophallus and orchiectomies with 
the creation of a neovagina, which are permanent procedures [7]. In recent years, these 
efforts have been extending into pediatric and adolescent populations. Adults, children 
and adolescents alike may choose to undergo only medical treatment or also include 
surgical interventions in order to function as their desired gender. 
  
 
In the prepubertal population, there is an additional treatment possibility, the 
suppression of puberty using continuous gonadotropin-releasing hormone (GnRH) 
agonists. Those in favor of the utilization of this treatment say the fundamental benefit of 
this strategy is that children gain time to reflect over their gender identity, without 
becoming trapped in a body that is experienced as alien [8]. The importance of 
preventing development of secondary sex characteristics during this period for those 
who support its usage feel it is detrimental. Supporters claim if children are experiencing 
considerable distress over their gender incongruence and proceed with natural pubertal 
development then they are at higher risk for further psychological distress and may be 
at risk for suicide, self-harm and similar behaviors [10]. Supporters claim that 
suppressing puberty and allowing children the opportunity to explore their gender 
identities decrease their risk for suicidal ideation and attempts. 
Those who may proceed with a gender transition will have more success in 
obtaining a more normal and satisfying appearance if puberty is arrested than if they 
had waited until adulthood to transition [10]. This is because natural effects of puberty 
such as matured height would be irreversible, or those effects that can be changed 
(mature breast and mature genital development) would only be reversed through in 
depth surgical procedures.  
Further, youth experiencing gender dysphoria who received treatment via 
puberty suppression have ample psychosocial outcomes, such as greater comfort with 
their physical selves therefore resulting in fewer psychological complications. Should 
youth on puberty suppressive medications decide not to change gender afterall, puberty 
suppressant drugs can be withheld and development restarts as normal [2]. Supporters 
profess that prepubescent children should be able to receive this treatment as long as 
the clinician discusses all potential risks and benefits. Indicating that since puberty 
suppression is the only therapy available for children with GD, those in favor for it’s 
usage consider it unethical to deny this treatment option. 
It is currently recommended that treatment be initiated when the patient is in the 
Tanner II stage of puberty on the basis that during this stage a child has had some 
experience of his/her biological gender and can therefore make a logical decision [2]. 
There is data that indicate that children who continue to experience gender dysphoria 
into early adolescence will maintain a transgender identity, and delaying treatment may 
cause further psychological effects [2]. Supporters stake their ethical argument on the 
notion that if allowing puberty to progress appears likely to harm the child then puberty 
should be suspended.  Indicating that it would be unethical to allow a patient to suffer 
through the distress of natural pubertal development when medicine can combat the 
distress it causes.  
         3. The case against puberty suppression and similar medical interventions 
As health care professionals, there is a moral obligation to alleviate suffering—
and for pediatric patients with GD, who are undoubtedly suffering, suppression of 
puberty may present as a plausible possibility to manage this illness, however the 
evidence based medicine to which medical interventions are founded upon is limited on 
  
 
this subject, and therefore there is insufficient indication of  this method being the safest 
way to relieve suffering for these individuals.  
Of course, it is worthwhile to note that exogenous continuous GnRH 
administration is the standard of care for the treatment of precocious puberty, and  for 
this population its safety and efficacy has been extensively studied [20]. The 
circumstances of utilizing GnRH in these populations and in those of young desiring to 
delay or stop puberty all together, in some case well beyond natural pubertal timelines, 
is distinguishable. Precocious puberty can be defined as sex hormone production or 
exposure occurring earlier than the norms for specific gender and racial or ethnic 
background. Identification of the child with pathological pubertal development allows for 
accurate diagnosis and application of current treatment strategies, which include to use 
of GnRHa treatment outlet such a implants, or injections [20]. Recent improvements in 
therapeutic agents allow for complete suppression of precocious puberty with less 
discomfort to the patient. Although approved for use by the FDA and pediatric 
endocrinology associations, there are major gaps in understanding and in the area of 
long-term outcomes, including endocrine and metabolic effects of precocious puberty 
[20]. Deficits occur in lack of long-term data on the psychological and behavioral effects 
of precocious puberty and the effects of GnRHa treatment. However, treatment in these 
populations suppress puberty only until typical pubertal stages are expected, and in 
many cases the child will go on to experience normal pubertal progression [20]. On the 
contrary, children receiving suppression medications during puberty, which is the 
recommended course of treatment for those with GD, do not typically go on to progress 
into further stages of puberty. In a review of extensive literature, there is no evidence of 
any large, randomized, controlled study that documents the alleged benefits and 
potential harms to gender dysphoric children from pubertal suppression and decades of 
cross-sex hormone use [22]. Further there seems to be no evidence of any long-term, 
large, randomized, controlled study which compares the outcomes of various 
psychotherapeutic interventions for childhood GD with those of pubertal suppression 
followed by decades of synthetic steroids [22].In a modern society which attribute 
pivotal medical successes on the basis of evidence-based medicine, this should give 
health care practitioners, families, and the society at large a pause.  
   3.1  Evidence based medicine as an ethical implication 
Evidence-based medicine is founded on the idea that decisions about the 
care of individual patients should involve the “conscientious, explicit and judicious 
use of current best evidence”[23]. Evidence based medicine is what guides to 
improvements in knowledge and thereby benefiting the patient’s overall well being. 
From an ethical perspective, the strongest arguments in support of evidence based 
medicine are that it allows the best evaluated methods of healthcare  as well as 
potentially harmful methods to be identified and enables patients and doctors to 
make better informed decisions.  If a particular medical procedure or treatment has 
sufficient evidence which would indicate in almost every circumstance, a positive 
effect on the patient experiencing the treatment without causing physical, emotional 
or psychological distress then after extensive clinical trials and further 
recommendations by prestigious medical research organizations, a medical 
  
 
procedure or treatment may be considered justified and beneficial. In the case 
against the use of puberty suppression medication and similar  treatments to 
manage GD in youth, there is no such context to which evidence based practice can 
be attributed. In a illustrative sense we might consider, a patient who has obvious 
emotional and psychological distress that requests a medical treatment or procedure 
which may, or may not relieve distress, the course of action which they are 
requesting is purely experimental, do we implement this request to honor the 
patient’s desires? This case would be further complicated if the patient was unable to 
consent fully due to a lack of competence, or an immature neurological presentation. 
In most circumstances, a provider would halt, ensuring more than adequate risk 
versus benefit research and sound evidence based literature was evaluated prior to 
proceeding with a course of action, granted it is ethically justified. It is dangerous and 
ethically concerning to recommend or provide treatment which involves a minor 
undergoing  medical treatment without the existence of a pathophysiology, and for 
such reasons it must be considered medical experimentation that does not justify the 
risk to which youth are exposed. Gender dysphoria is currently the only circumstance 
in which medical intervention does not cure a sick body, but healthy organs are 
mutilated in the process of adapting physical and congruent psychological identity.  
3.2  Risk of harm as an ethical implication  
The claim that puberty-blocking treatments are fully reversible makes them 
appear less drastic, but this claim is not supported by scientific evidence. As addressed 
in previous sections, it remains unknown whether or not ordinary sex-typical puberty will 
resume following the suppression of puberty in patients with gender dysphoria [9]. 
Additionally, there is evidence which suggests children receiving suppression 
medications during puberty or prior to puberty do not typically go on to progress into 
further stages of puberty, altogether disrupting or eliminating natural puberty and 
replacing it with cross-hormonal therapy [9]. 
 
In a study of seventy pre-pubertal candidates that continued on to receive 
puberty suppression it was documented that all subjects eventually embraced a 
transgender identity and requested cross-sex hormones [11]. This statistic is alarming. 
In typical cases of diagnosed GD eighty to ninety five percent of pre-pubertal youth do 
not persist in their GD. Studies that show one hundred percent of pre-pubertal children 
who received puberty suppression choose to later initiate treatment with cross-sex 
hormones suggests that the use of such hormones may inevitably lead the individual to 
identify as transgender, due to underlying mechanisms which occur within neurological 
realms. The suppression of puberty prevents further endogenous masculinization or 
feminization of the brain causing exposed children to be non-conforming. Current 
recommendations involve the promotion of impersonation of an individual’s desired 
gender while being treated with puberty suppression drugs, inevitably forcing already 
confused children to take on the role of their non-biological sex [13]. These neurological 
implications will prevent a youth from identifying as being the biological male or a 
female they actually are, and could cause for further confusion or distress if they are 
unable to accurately impersonate the opposite gender. A protocol of pubertal 
suppression that sets into motion an inevitable outcome of transgender identification 
  
 
that requires lifelong use of harmful synthetic hormones [12] is neither fully reversible 
nor harmless. 
  It is also unclear whether children would be able to develop normal reproductive 
functions if they were to withdraw from puberty suppression [12]. There is further 
uncertainty on whether bone and muscle development will proceed normally for these 
children if they resume puberty as their biological sex. There is additional cause for 
concern when interfering with pubertal suppression at Tanner Stage 2, followed by the 
use of cross-sex hormones which will leave these children sterile and without gonadal 
tissue or gametes available for cryopreservation[12]. Sterilization of humans without 
medically acceptable and sound justification, is ethically and morally wrong. When an 
individual is sterilized, even as a secondary outcome of therapy, lacking full, free, and 
informed consent, it is a violation of international law.  The debate on pediatric consent 
will not be discussed in great detail here, however it is of important ethical consideration 
to note the implications of sterilizing a child without consent of their matured adult self 
should be reason to evaluate alternative treatment options.  
 
Other risks of pubertal suppression medications must be considered, and further 
invalidate the use of these drugs for treatment of youth with gender dysphoria. The 
GnRH agonists used for pubertal suppression in gender dysphoric children have been 
discussed in previous sections in detail. In addition to preventing the development of 
secondary sex characteristics, GnRH agonists have side effects which include arrest in 
bone growth, decrease bone accretion, prevention of the sex-steroid dependent 
organization and maturation of the youth brain, and as previously introduced, inhibit 
fertility by preventing the development of gonadal tissue and mature gametes for the 
duration of treatment. GnRH agonists prevent the maturation of gonadal tissue and 
gametes in both sexes, the large percent of youth who desire to initiate treatment using 
cross-sex hormones will be rendered infertile without any possibility of having genetic 
offspring in the future because they will lack gonadal tissue and gametes [12]. If 
guidelines were considered to delay use of puberty suppression medication until older 
adolescence, or adolescents in later Tanner stages of pubertal development, this may 
provide an opportunity for them to consider cryopreservation of gametes prior to 
beginning cross-sex hormones. However this induces the burden and costly  
interventions of using artificial reproductive technology in order to conceive genetic 
offspring in the future, which may be especially gruesome in cases where adolescents 
come to terms with their gender dysphoria after maturation of neurological brain 
development in the mid-twenties [13]. There have been documented cases of 
transgender adults who stopped their cross-sex hormones in order to allow their bodies 
to produce gametes, conceive, and have a child, there is little guarantee that this is a 
viable option in the long term  [12].. Those individuals who undergo sex reassignment 
surgery and have their reproductive organs removed are rendered permanently infertile 
[12]. 
3.3 Risk of harm from cross-sex hormones as an ethical implication  
Potential risks from cross-sex hormones to children with GD are based on the 
adult literature. In adult literature there are potentially long-term safety risks associated 
  
 
with hormone therapy, many findings have been deemed inconclusive [23]. Children 
who transition will require these hormones for a significantly greater length of time than 
their adult counterparts [7]. Due to this they may be more likely to experience 
physiological morbidities than those researched in adults. Oral estrogen administration 
to males put them at potential risk for experiencing: thrombosis/thromboembolism; 
cardiovascular disease; weight gain; hypertriglyceridemia; elevated blood pressure; 
decreased glucose tolerance; gallbladder disease; prolactinoma; and breast cancer 
[15]. Females who receive testosterone may be at risk for  low HDL and elevated 
triglycerides; increased homocysteine levels; hepatotoxicity; polycythemia; increased 
risk of sleep apnea; insulin resistance; and unknown effects on breast, endometrial and 
ovarian tissues [15]. In addition gender altering surgeries offered after cross-hormone 
completion carry its own set of irreversible risks. 
  3.4 Beneficence and non-maleficence for ethical consideration 
It is imperative  to note the ethical considerations of such risks involved when 
determining the morality of administering these medication and treatment options to 
children with gender dysphoria as a way to manage  their psychological distress. While 
it’s important to understand these efforts have been established in order to provide 
solace, and improve the overall psychological status of affected children, we must 
evaluate whether good intentions correlate to a greater overall good for these youth.  
Ensuring youth with gender dysphoria receive adequate medical treatment and care is 
undoubtedly the duty of medical professionals, however how we get to this is of 
important discussion. In medical ethics, the term beneficence connotes acts of mercy, 
kindness, and charity. It is understood even more broadly in ethical theory to include 
effectively all forms of action intended to benefit or promote the good of other persons. 
The  ethical guiding principle of beneficence refers to a normative statement of a moral 
obligation to act for the others' benefit, helping them to further their important and 
legitimate interests, often by preventing or removing possible harms. While there is the 
argument that inducing the evaluated medical treatments would in fact remove the harm 
of potentially fatal outcomes from increased suicide risks, or remove the harm of further 
psychological distress there isn’t enough evidence to support that proceeding with this 
course of treatment is the best or safest way to get to the end result. Those in support of 
this treatment, and those who oppose it have the same end result in mind, a positive, 
more fulfilling life with little to no psychological distress. The difference lies in how this 
goal is obtained and putting a youth at risk for many adverse side effects, when other, 
evidence based practices such as psychological counseling and therapy have been 
proven to be successful in alleviating distress is not ethically sound. In addition to a 
moral obligation to beneficence, health care professionals have a moral obligation to 
non-maleficence.  By implementing a treatment with an increase in harmful risks that 
could substantially harm the receiving patient we are not fulfilling our moral obligation to 
do no harm and further do an injustice to our patient by neglecting to address the 
underlying issues for psychological distress that is experienced in youth with gender 
dysphoria.  
  
  
 
3.5 Psychological implications for ethical consideration 
 Further psychological implications suggest there is a more beneficial treatment 
for youth facing gender dysphoria that should be considered in place of initiating 
pubertal suppression treatments and similar methods for care. There is certainly 
evidence of a social contagion at play for those facing GD. For example, in many 
communities, there are entire peer groups coming out or being diagnosed with gender 
dysphoria and identifying as transgender at the same time [14]. Strong consideration 
should be given to investigating a causal association between adverse childhood 
events, including sexual abuse, and transgenderism, as addressed in previous sections 
there is large body of literature documenting many potential causes for the onset of GD 
[15]. It must be considered possible that some individuals develop GD and later claim a 
transgender identity as a result of childhood maltreatment and/or sexual abuse. This is 
an area in need of research, however if it is so then the same approach used similar 
psychological contexts should be considered, such as intensive psychological therapy 
and not the use of medical interventions like puberty suppression medications. The 
American Psychiatric Association (APA), explains in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) that GD is listed therein not due to the discrepancy 
between the individual’s thoughts and physical reality, but due to the presence of 
emotional distress that hampers social functioning [16]. The DSM-5 states a diagnosis 
is needed in order for insurance companies to pay for the treatments of discussion 
(puberty suppression medication) in order to alleviate the emotional distress of GD [16].  
In the case of GD proceeding with medical interventions such as GRnH, and cross-
hormone therapy are not only emotionally distressing for the individuals but also life-
threatening. In this population those who desire surgery or additional extreme medical 
interventions may very well be relieved of some emotional distress but these 
procedures will do nothing to address the underlying psychological problem. With many 
psychological disorders, if underlying issues are left unaddressed there is a risk that the 
patient will develop worse conditions, or could potentially cause indirect harm by 
increasing risk for suicide, depression and anxiety. According to the DSM-5, once 
treatment with these medications or surgical intervention have been induced, and 
distress is considered alleviated [16], then GD diagnosis is no longer applicable, thereby 
disengaging funds for the patient to receive therapeutic intervention and potentially 
posing a risk for further or worsened distress. If we aren’t cautious in this regard then 
the art of psychotherapy will diminish as the field increasingly devolves into potentially 
unnecessary medical interventions, with the risk of devastating results for patient 
 It has been standard practice for a physician or psychologist to help  an 
individual to align their thoughts with physical reality. In the case of gender dysphoria, 
for an individual’s gender identity to align with biologic sex. Children with GD do not 
have a disordered body, although they may feel as they do, it can be assumed in most 
presentations their body is perfectly healthy. A child’s distress over developing 
secondary sex characteristics does not mean that puberty should be treated as a 
disease to be halted, but rather a phenomenon in need of further evaluation through 
psychoanalysis. Up until recent years children presenting with GD  were treated with the 
approach of watchful waiting or pursuit of family and individual psychotherapy [16]. The 
  
 
goal of therapy, was to address familial conflicts, treat any psychosocial morbidities in 
the child, and aid the child in aligning gender identity with biological sex [16]. Experts on 
both sides of the pubertal suppression debate agree that within this context, the majority 
of children with GD accepted their biological sex by late adolescence (see previous 
sections for statistics). The increase in utilizing pubertal suppression to treat GD is 
promoted in order to avoid discrimination, violence, psychopathology, and suicide. 
Which supporters claim are inevitable consequences if withholding of puberty blockers 
or cross-sex hormones from a gender dysphoric child occurs. Yet, statistics revealing 
that eighty to ninety five percent of gender-dysphoric youth emerge physically and 
psychologically intact after passing through puberty without these interventions refute 
this claim [1]. With evidence emphasizing the effectiveness of psychotherapy in youth 
with GD [17], the cornerstone for suicide prevention or psychological distress prevention 
should be the same for them as for all children facing psychological disorders. That is 
with early identification and treatment of psychological comorbidities. If other treatment 
options exist which provide decreased implications and are supported with in depth 
analysis to be safe and effective in an attempt to preserve, honor and promote the good 
for human life, then these treatment options must be the standard of care to conflicting 
treatment options which could result in harm, maleficence and fail to honor the greater 
good of the patient.   
 4. Conclusion  
 In closing the ethical considerations outlined and analyzed in this essay 
involve illuminating an understanding of whether the administering pubertal suppression 
with GnRH agonists, and cross-sex hormones to children with gender dysphoria are a 
morally justified treatment to manage their psychological distress, or if safer more 
understood alternatives exist. The importance of providing treatment options in this 
population is essential in order to provide solace, and improve the overall psychological 
status of affected children. The use of pubertal suppression drugs and cross-sex 
hormones have been considered as a possible treatment option in order to achieve this 
goal. However, it is crucial that health care professionals understand and consider that  
good intentions do not indefinitely correlate to a greater overall good for these youth, 
especially in the case of these interventions. Ensuring youth with gender dysphoria 
receive adequate medical treatment and care is undoubtedly the duty of medical 
professionals as indicated in this essay, however the use of inconclusive and under 
researched methods [17] to manage gender dysphoria cannot be ethically justified and 
therefore should be re-evaluated.  
Providing potentially harmful and ultimately uncertain treatment to our future 
generation should not be the standard care when there are treatment alternatives 
available with empirical evidence supporting its effectiveness, such as psychotherapy. 
Of course implementing appropriate interventions for  gender dysphoria in the pediatric 
and adolescent population is certainly needed, therefore we must continue to treat with 
proven and safe methods while simultaneously researching more treatment options. 
The use pubertal suppression with GnRH agonists, and cross-sex hormones in minors 
may very well be an option in the future, but without more than sufficient and successful 
  
 
long-term clinical trials [17], conclusive analysis on risk/benefits ratio, appropriate 
initiation of safety protocols and FDA approval among other administrative 
recommendations, these treatment methods cannot be utilized in an ethically 
appropriate manner. Looking at future directions, appropriate longitudinal studies should 
be performed, with consent and disclosure of the potential risks discussed previously, in 
order to clarify safety concerns or lack thereof. Conclusive and sufficient evidence of 
long term safety and evaluation must be performed in order to align with evidence 
based medicine guidelines, and further considerations such as ensuring minimal harm 
to the patient both in the present as well as in the future in order to uphold ethical 
guiding principles which support the overall good for the patient of discussion. From an 
ethical standpoint it is not morally justified to provide pubertal suppression medications, 
and cross-sex hormones to minor populations until further evaluation of such methods 
for treatment are performed instead, we should rely on evidence based and safer 
methods for treatment such as psychotherapy.  
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